CCL2 and sarcoidosis: Therefore, our observations that Montelukast can reduce CCL2 for at least a subgroup of sarcoidosis patients may have its explanation in a combination of heterogeneity in Montelukast efficacy, patient differences and the complex nature of exosomes.